CoChat

Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms

Open access
Moratalla, Rosario, Khairnar, Amit, Simola, Nicola, Granado, Noelia, García-Montes, Jose Ruben, Porceddu, Pier Francesca, Tizabi, Yousef, Costa, Giulia, Morelli, Micaela · 2017 · Progress in Neurobiology
Cited by 225

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

HIGHLIGHTSMDMA damages serotonergic system in primates and rats and dopaminergic system in mice.METH damages the dopaminergic system in all animal species including humans.The nigrostriatal system is more vulnerable than the mesolimbic system.Within the striatum the striosomes are more vulnerable than the matrix.METH kills dopamine neurons as demonstrated by silver‐staining in rodents.METH reduces DAT binding sites and motor skills in human addicts. ABSTRACT Amphetamine‐related drugs, such as 3,4‐methylenedioxymethamphetamine (MDMA) and methamphetamine (METH), are popular recreational psychostimulants. Several preclinical studies have demonstrated that, besides having the potential for abuse, amphetamine‐related drugs may also elicit neurotoxic and neuroinflammatory effects. The neurotoxic potentials of MDMA and METH to dopaminergic and serotonergic neurons have been clearly demonstrated in both rodents and non‐human primates. This review summarizes the species‐specific cellular and molecular mechanisms involved in MDMA and METH‐mediated neurotoxic and neuroinflammatory effects, along with the most important behavioral changes elicited by these substances in experimental animals and humans. Emphasis is placed on the neuropsychological and neurological consequences associated with the neuronal damage. Moreover, we point out the gap in our knowledge and the need for developing appropriate therapeutic strategies to manage the neurological problems associated with amphetamine‐related drug abuse.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pneurobio.2015.09.011

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 319

  1. Adori, 2006, Damage of serotonergic axons and immunolocalization of Hsp27, Hsp72, and Hsp90 molecular chaperones after a single dose of MDMA administration in dark agouti rat: temporal, spatial, and cellular patterns, J. Comp. Neurol., 497, 251, 10.1002/cne.20994 · DOI
  2. Afonso-Oramas, 2009, Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease, Neurobiol. Dis., 36, 494, 10.1016/j.nbd.2009.09.002 · DOI · Paper page
  3. Aguirre, 1999, Alpha-lipoic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity, NeuroReport, 10, 3675, 10.1097/00001756-199911260-00039 · DOI
  4. Albers, 1995, Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents, J. Pharmacol. Exp. Ther., 275, 1104, 10.1016/S0022-3565(25)12160-5 · DOI · Paper page
  5. Alles, 1993, The comparative physiological actions of the dl-B-phenylisopropylamines. I. Pressor effect and toxicity, J. Pharmacol. Exp. Ther., 47, 339, 10.1016/S0022-3565(25)08045-0 · DOI
  6. Aloisi, 2001, Immune function of microglia, Glia, 36, 165, 10.1002/glia.1106 · DOI · Paper page
  7. Alves, 2007, Monoamine oxidase-B mediates ecstasy-induced neurotoxic effects to adolescent rat brain mitochondria, J. Neurosci., 27, 10203, 10.1523/JNEUROSCI.2645-07.2007 · DOI
  8. Andres, 2015, Methamphetamine acutely inhibits voltage-gated calcium channels but chronically up-regulates L-type channels, J. Neurochem., 10.1111/jnc.13104 · DOI
  9. Angoa-Pérez, 2013, Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA, J. Neurochem., 125, 102, 10.1111/jnc.12114 · DOI
  10. Angulo, 2004, Antagonists of the neurokinin-1 or dopamine D1 receptors confer protection from methamphetamine on dopamine terminals of the mouse striatum, Ann. N. Y. Acad. Sci., 1025, 171, 10.1196/annals.1316.022 · doi:10.1196/annals.1316.022
  11. Anneken, 2013, MDMA increases glutamate release and reduces parvalbumin-positive GABAergic cells in the dorsal hippocampus of the rat: role of cyclooxygenase, J. Neuroimmune Pharmacol., 8, 58, 10.1007/s11481-012-9420-x · DOI · Paper page
  12. Ares-Santos, 2012, Dopamine D(1) receptor deletion strongly reduces neurotoxic effects of methamphetamine, Neurobiol. Dis., 45, 810, 10.1016/j.nbd.2011.11.005 · DOI · Paper page
  13. Ares-Santos, 2013, The role of dopamine receptors in the neurotoxicity of methamphetamine, J. Intern. Med., 273, 437, 10.1111/joim.12049 · DOI · Paper page
  14. Ares-Santos, 2014, Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining, Neuropsychopharmacology, 39, 1066, 10.1038/npp.2013.307 · DOI
  15. Bai, 2001, Serotonergic neurotoxicity of 3,4-(+/−)-methylenedioxyamphetamine and 3,4-(+/−)-methylenedioxymethamphetamine (Ecstasy) is potentiated by inhibition of gamma-glutamyl transpeptidase, Chem. Res. Toxicol., 14, 863, 10.1021/tx010011l · DOI
  16. Barbosa, 2014, “Ecstasy”-induced toxicity in SH-SY5Y differentiated cells: role of hyperthermia and metabolites, Arch. Toxicol., 88, 515, 10.1007/s00204-013-1147-9 · DOI
  17. Barcia, 2011, IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease, Cell. Death Dis., 2, e142, 10.1038/cddis.2011.17 · DOI · Paper page
  18. Battaglia, 1987, 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites, J. Pharmacol. Exp. Ther., 242, 911, 10.1016/S0022-3565(25)39191-3 · DOI · Paper page
  19. Battaglia, 2002, Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity, J. Neurosci., 22, 2135, 10.1523/JNEUROSCI.22-06-02135.2002 · DOI · Paper page
  20. Bauernfeind, 2011, Human Ecstasy use is associated with increased cortical excitability: an fMRI study, Neuropsychopharmacology, 36, 1127, 10.1038/npp.2010.244 · DOI
  21. Beauvais, 2011, Involvement of dopamine receptors in binge methamphetamine-induced activation of endoplasmic reticulum and mitochondrial stress pathways, PLoS ONE, 6, e28946, 10.1371/journal.pone.0028946 · DOI · Paper page
  22. Benamar, 2008, A new brain area affected by 3,4 methylenedioxymethamphetamine: a microdialysis-biotelemetry study, Eur. J. Pharmacol., 596, 84, 10.1016/j.ejphar.2008.08.001 · doi:10.1016/j.ejphar.2008.08.001
  23. Benningfield, 2013, Brain serotonin function in MDMA (ecstasy) users: evidence for persisting neurotoxicity, Neuropsychopharmacology, 38, 253, 10.1038/npp.2012.178 · DOI
  24. Benzenhöfer, 2010, Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin, Addiction, 105, 1355, 10.1111/j.1360-0443.2010.02948.x · DOI
  25. Bezard, 2006, 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease, Neurobiol. Dis., 23, 77, 10.1016/j.nbd.2006.02.003 · DOI
  26. Bourne, 2001, SCH 23390 the first selective dopamine D1-like receptor antagonist, CNS Drug Rev., 7, 399, 10.1111/j.1527-3458.2001.tb00207.x · DOI · Paper page
  27. Bowyer, 2001, Phenobarbital and dizocilpine can block methamphetamine-induced neurotoxicity in mice by mechanisms that are independent of thermoregulation, Brain Res., 919, 179, 10.1016/S0006-8993(01)03051-7 · doi:10.1016/s0006-8993(01)03051-7
  28. Bowyer, 2008, Neurotoxic-related changes in tyrosine hydroxylase, microglia, myelin, and the blood–brain barrier in the caudate-putamen from acute methamphetamine exposure, Synapse, 62, 193, 10.1002/syn.20478 · DOI · Paper page
  29. Brodkin, 1993, Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity, Pharmacol. Biochem. Behav., 45, 647, 10.1016/0091-3057(93)90520-4 · DOI
  30. Broening, 2005, Interactions of dopamine D1 and D2 receptor antagonists with d-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions, Synapse, 56, 84, 10.1002/syn.20130 · DOI
  31. Bronstein, 1995, Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality, J. Pharmacol. Exp. Ther., 274, 943, 10.1016/S0022-3565(25)10672-1 · DOI
  32. Brown, 2003, Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress, Pharmacol. Ther., 99, 45, 10.1016/S0163-7258(03)00052-4 · DOI · Paper page
  33. Brown, 2005, Methamphetamine induced inhibition of mitochondrial complex II: roles of glutamate and peroxynitrite, J. Neurochem., 95, 429, 10.1111/j.1471-4159.2005.03379.x · DOI · Paper page
  34. Brown, 2006, Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression, J. Neurochem., 98, 495, 10.1111/j.1471-4159.2006.03902.x · doi:10.1111/j.1471-4159.2006.03902.x
  35. Bruno, 1993, Excitatory amino acids and neurotoxicity, Funct. Neurol., 8, 279
  36. Buchert, 2006, Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users, Eur. J. Nucl. Med. Mol. Imaging, 33, 188, 10.1007/s00259-005-1850-8 · DOI
  37. Burke, 1993, Relative loss of the striatal striosome compartment, defined by calbindin-D28k immunostaining, following developmental hypoxic-ischemic injury, Neuroscience, 56, 305, 10.1016/0306-4522(93)90333-B · DOI
  38. Büttner, 2006, Neuropathological alterations in drug abusers: the involvement of neurons, glial, and vascular systems, Forensic Sci. Med. Pathol., 2, 115, 10.1385/FSMP:2:2:115 · DOI
  39. Büttner, 2011, Review: the neuropathology of drug abuse, Neuropathol. Appl. Neurobiol., 37, 118, 10.1111/j.1365-2990.2010.01131.x · DOI · Paper page
  40. Cadet, 2001, Involvement of free radicals in MDMA-induced neurotoxicity in mice, Ann. Med. Interne (Paris), 152, IS57
  41. Cai, 2008, The combination of methamphetamine and of the HIV protein, Tat, induces death of the human neuroblastoma cell line, SH-SY5Y, Synapse, 62, 551, 10.1002/syn.20512 · doi:10.1002/syn.20512
  42. Caligiuri, 2005, Do preclinical findings of methamphetamine-induced motor abnormalities translate to an observable clinical phenotype?, Neuropsychopharmacology, 30, 2125, 10.1038/sj.npp.1300859 · DOI
  43. Callaghan, 2010, Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders, Mov. Disord., 25, 2333, 10.1002/mds.23263 · DOI · Paper page
  44. Callaghan, 2012, Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs, Drug Alcohol Depend., 120, 35, 10.1016/j.drugalcdep.2011.06.013 · DOI · Paper page
  45. Callier, 2003, Evolution and cell biology of dopamine receptors in vertebrates, Biol. Cell, 95, 489, 10.1016/S0248-4900(03)00089-3 · DOI · Paper page
  46. Capela, 2006, Neurotoxicity of Ecstasy metabolites in rat cortical neurons, and influence of hyperthermia, J. Pharmacol. Exp. Ther., 316, 53, 10.1124/jpet.105.092577 · DOI
  47. Capela, 2006, Ecstasy-induced cell death in cortical neuronal cultures is serotonin 2A-receptor dependent and potentiated under hyperthermia, Neuroscience, 139, 1069, 10.1016/j.neuroscience.2006.01.007 · DOI
  48. Capela, 2009, Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview, Mol. Neurobiol., 39, 210, 10.1007/s12035-009-8064-1 · DOI · Paper page
  49. Cappon, 2000, Time-course of methamphetamine-induced neurotoxicity in rat caudate-putamen after single-dose treatment, Brain Res., 863, 106, 10.1016/S0006-8993(00)02107-7 · DOI
  50. Carmena, 2015, Methamphetamine-induced toxicity in indusium griseum of mice is associated with astro- and microgliosis, Neurotox. Res., 27, 209, 10.1007/s12640-014-9505-9 · DOI
  51. Chang, 2007, Structural and metabolic brain changes in the striatum associated with methamphetamine abuse, Addiction, 102, 16, 10.1111/j.1360-0443.2006.01782.x · DOI · Paper page
  52. Chen, 2004, D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade, J. Biol. Chem., 279, 39317, 10.1074/jbc.M403891200 · DOI · Paper page
  53. Chen, 2013, RNA interference targeting α-synuclein attenuates methamphetamine-induced neurotoxicity in SH-SY5Y cells, Brain Res., 1521, 59, 10.1016/j.brainres.2013.05.016 · DOI
  54. Chipana, 2008, Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents, Neuropharmacology, 54, 1254, 10.1016/j.neuropharm.2008.04.003 · DOI
  55. Chomchai, 2010, Methamphetamine abuse during pregnancy and its health impact on neonates born at Siriraj Hospital, Bangkok, Thailand, Southeast Asian J. Trop. Med. Public Health, 35, 228
  56. Christine, 2010, Parkinsonism in patients with a history of amphetamine exposure, Mov. Disord., 25, 228, 10.1002/mds.22915 · DOI
  57. Chu, 2010, Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release, J. Neurochem., 115, 325, 10.1111/j.1471-4159.2010.06922.x · DOI
  58. Cisneros, 2012, HIV-1, methamphetamine and astrocyte glutamate regulation: combined excitotoxic implications for neuro-AIDS, Curr. HIV Res., 10, 392, 10.2174/157016212802138832 · DOI
  59. Colado, 1995, The hyperthermic and neurotoxic effects of “ecstasy” (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in the dark agouti (DA) rat, a model of the cyp2d6 poor metabolizer phenotype, Br. J. Pharmacol., 115, 1281, 10.1111/j.1476-5381.1995.tb15037.x · DOI · Paper page
  60. Colado, 1998, Role of hyperthermia in the protective action of chlomethiazole against MDMA (“ecstasy”)-induced neurodegeneration, comparison with the novel NMDA channel blocker AR-R15896AR, Br. J. Pharmacol., 124, 479, 10.1038/sj.bjp.0701859 · DOI
  61. Colado, 2001, A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) on dopamine neurones in mouse brain, Br. J. Pharmacol., 134, 1711, 10.1038/sj.bjp.0704435 · DOI
  62. Commins, 1987, Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain, J. Pharmacol. Exp. Ther., 241, 338, 10.1016/S0022-5347(25)00317-9 · DOI · Paper page
  63. Costa, 2013, MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice, Mov. Disord., 28, 1957, 10.1002/mds.25646 · DOI
  64. Costa, 2014, MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex, Psychopharmacology (Berl.), 231, 4007, 10.1007/s00213-014-3536-z · DOI
  65. Cox, 2014, Behavioral and neurochemical effects of repeated MDMA administration during late adolescence in the rat, Prog. Neuropsychopharmacol. Biol. Psychiatry, 48, 229, 10.1016/j.pnpbp.2013.09.021 · DOI
  66. Cozzi, 1999, Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines, Eur. J. Pharmacol., 381, 63, 10.1016/S0014-2999(99)00538-5 · DOI · Paper page
  67. Crawford, 2006, Neonatal 3,4-methylenedioxymethamphetamine (MDMA) exposure alters neuronal protein kinase A activity, serotonin and dopamine content, and [35S]GTPgammaS binding in adult rats, Brain Res., 1077, 178, 10.1016/j.brainres.2006.01.017 · DOI
  68. Cubells, 1994, Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress, J. Neurosci., 14, 2260, 10.1523/JNEUROSCI.14-04-02260.1994 · DOI · Paper page
  69. Cunningham, 2003, Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine-related hospital admissions, Addiction, 98, 1229, 10.1046/j.1360-0443.2003.00450.x · DOI
  70. Cunningham, 2008, Impact of methamphetamine precursor legislation, a suppression policy, on the demand for drug treatment, Soc. Sci. Med., 66, 1463, 10.1016/j.socscimed.2007.12.006 · DOI
  71. Cunningham, 2008, Methamphetamine suppression and route of administration: precursor regulation impacts on snorting, smoking, swallowing and injecting, Addiction, 103, 1174, 10.1111/j.1360-0443.2008.02208.x · DOI
  72. Curtin, 2015, Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based assessment, Drug Alcohol Depend., 146, 30, 10.1016/j.drugalcdep.2014.10.027 · DOI · Paper page
  73. Dafters, 1998, Persistent loss of thermoregulation in the rat induced by 3,4-methylenedioxymethamphetamine (MDMA or “ecstasy”) but not by fenfluramine, Psychopharmacology (Berl.), 138, 207, 10.1007/s002130050664 · DOI
  74. Darmopil, 2009, Genetic inactivation of dopamine D1 but not D2 receptors inhibits l-DOPA-induced dyskinesia and histone activation, Biol. Psychiatry, 66, 603, 10.1016/j.biopsych.2009.04.025 · DOI · Paper page
  75. Darvas, 2009, Restriction of dopamine signaling to the dorsolateral striatum is sufficient for many cognitive behaviors, Proc. Natl. Acad. Sci. U. S. A., 106, 14664, 10.1073/pnas.0907299106 · DOI · Paper page
  76. Darvas, 2010, Restricting dopaminergic signaling to either dorsolateral or medial striatum facilitates cognition, J. Neurosci., 30, 1158, 10.1523/JNEUROSCI.4576-09.2010 · DOI · Paper page
  77. Daumann, 2004, Neural mechanisms of working memory in ecstasy (MDMA) users who continue or discontinue ecstasy and amphetamine use: evidence from an 18-month longitudinal functional magnetic resonance imaging study, Biol. Psychiatry, 56, 349, 10.1016/j.biopsych.2004.06.011 · DOI
  78. Daumann, 2005, Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4-methylenedioxymethamphetamine) users, Psychopharmacology (Berl.), 180, 607, 10.1007/s00213-004-2002-8 · DOI
  79. Davison, 1997, Ecstasy (MDMA) in recreational users: self-reported psychological and physiological effects, Hum. Psychopharmacol., 12, 221, 10.1002/(SICI)1099-1077(199705/06)12:3<221::AID-HUP854>3.0.CO;2-C · DOI · Paper page
  80. de la Torre, 2000, Pharmacology of MDMA in humans, Ann. N. Y. Acad. Sci., 914, 225, 10.1111/j.1749-6632.2000.tb05199.x · DOI · Paper page
  81. de la Torre, 2004, Clinical pharmacokinetics of amfetamine and related substances monitoring in conventional and non-conventional matrices, Clin. Pharmacokinet., 43, 157, 10.2165/00003088-200443030-00002 · DOI
  82. De Mei, 2009, Getting specialized: presynaptic and postsynaptic dopamine D2 receptors, Curr. Opin. Pharmacol., 9, 53, 10.1016/j.coph.2008.12.002 · DOI · Paper page
  83. Deng, 2007, Methamphetamine administration causes death of dopaminergic neurons in the mouse olfactory bulb, Biol. Psychiatry, 61, 1235, 10.1016/j.biopsych.2006.09.010 · DOI
  84. Derlet, 1990, Methamphetamine. Stimulant of the 1990s?, West. J. Med., 153, 625
  85. De Vito, 1989, Methamphetamine-induced neuronal damage: a possible role for free radicals, Neuropharmacology, 28, 1145, 10.1016/0028-3908(89)90130-5 · DOI · Paper page
  86. Di Iorio, 2012, Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users, Arch. Gen. Psychiatry, 69, 399, 10.1001/archgenpsychiatry.2011.156 · DOI
  87. Dickinson, 1999, Dopamine D2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum, J. Neurochem., 72, 148, 10.1046/j.1471-4159.1999.0720148.x · DOI · Paper page
  88. Donaldson, 2006, Oral health of the methamphetamine abuser, Am. J. Health-Syst. Pharm., 63, 2078, 10.2146/ajhp060198 · DOI · Paper page
  89. Downey, 2014, Altered energy production, lowered antioxidant potential, and inflammatory processes mediate CNS damage associated with abuse of the psychostimulants MDMA and methamphetamine, Eur. J. Pharmacol., 727, 125, 10.1016/j.ejphar.2014.01.032 · DOI
  90. Downing, 1986, The psychological and physiological effects of MDMA on normal volunteers, J. Psychoactive Drugs, 18, 335, 10.1080/02791072.1986.10472366 · DOI · Paper page
  91. Easton, 2003, Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of alpha-methyldopamine with relevance to MDA and MDMA (ecstasy), Brain Res., 987, 144, 10.1016/S0006-8993(03)03319-5 · DOI
  92. Eisch, 1998, Methamphetamine neurotoxicity: dissociation of striatal dopamine terminal damage from parietal cortical cell body injury, Synapse, 30, 433, 10.1002/(SICI)1098-2396(199812)30:4<433::AID-SYN10>3.0.CO;2-O · DOI · Paper page
  93. Escobedo, 2005, A comparative study on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine (HHMA) on brain monoamine levels after i.p. or striatal administration in mice, Br. J. Pharmacol., 144, 231, 10.1038/sj.bjp.0706071 · DOI
  94. Espadas, 2012, l-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function, Neurobiol. Dis., 48, 271, 10.1016/j.nbd.2012.07.012 · DOI
  95. Esteban, 2001, 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose, Psychopharmacology (Berl.), 154, 251, 10.1007/s002130000645 · DOI · Paper page
  96. Fantegrossi, 2003, Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine (“ecstasy”) and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice, Psychopharmacology (Berl.), 166, 202, 10.1007/s00213-002-1261-5 · DOI
  97. Fantegrossi, 2008, A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse, Neuroscience, 151, 533, 10.1016/j.neuroscience.2007.11.007 · DOI
  98. Farfel, 1992, The antagonist MK-801 protects against serotonin depletions induced by methamphetamine 3,4-methylenedioxymethamphetamine and p-chloroamphetamine, Brain Res., 595, 121, 10.1016/0006-8993(92)91460-V · DOI
  99. Farré, 2004, Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics, Psychopharmacology (Berl.), 173, 364, 10.1007/s00213-004-1789-7 · DOI · Paper page
  100. Faunt, 1987, The effects of selective dopamine receptor agonists and antagonists on body temperature in rats, Eur. J. Pharmacol., 133, 243, 10.1016/0014-2999(87)90019-7 · doi:10.1016/0014-2999(87)90019-7
  101. Ferreira, 2013, Neurotoxicity of “ecstasy” and its metabolites in human dopaminergic differentiated SH-SY5Y cells, Toxicol. Lett., 216, 159, 10.1016/j.toxlet.2012.11.015 · DOI
  102. Finnegan, 1989, The N-methyl-d-aspartate (NMDA) receptor antagonist, dextrorphan, prevents the neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats, Neurosci. Lett., 105, 300, 10.1016/0304-3940(89)90637-X · DOI
  103. Fischer, 1995, Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/−)3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”), J. Neurosci., 15, 5476, 10.1523/JNEUROSCI.15-08-05476.1995 · DOI · Paper page
  104. Flaum, 1996, When does amphetamine-induced psychosis become schizophrenia?, Am. J. Psychiatry, 153, 812, 10.1176/ajp.153.6.812 · DOI · Paper page
  105. Fornai, 2004, DNA damage and ubiquitinated neuronal inclusions in the substantia nigra and striatum of mice following MDMA (ecstasy), Psychopharmacology (Berl.), 173, 353, 10.1007/s00213-003-1708-3 · DOI
  106. Frau, 2013, Contribution of caffeine to the psychostimulant, neuroinflammatory and neurotoxic effects of amphetamine-related drugs, J. Caffeine Res., 3, 79, 10.1089/jcr.2013.0007 · DOI
  107. Frau, 2013, Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility, J. Neurochem., 124, 69, 10.1111/jnc.12060 · DOI
  108. Frederick, 1995, Behavioral and neurochemical effects of chronic methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys, Neurotoxicol. Teratol., 17, 531, 10.1016/0892-0362(95)00013-H · DOI
  109. Frederick, 1998, Acute effects of fexfenfluramine (D-FEN) and methylenedioxymethamphetamine (MDMA) before and after short-course, high-dose treatment, Ann. N. Y. Acad. Sci., 844, 183, 10.1111/j.1749-6632.1998.tb08233.x · DOI
  110. Freudenmann, 2006, The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents, Addiction, 101, 1241, 10.1111/j.1360-0443.2006.01511.x · DOI · Paper page
  111. Friend, 2013, A role for D1 dopamine receptors in striatal methamphetamine-induced neurotoxicity, Neurosci. Lett., 555, 243, 10.1016/j.neulet.2013.08.039 · doi:10.1016/j.neulet.2013.08.039
  112. Fuller, 1992, Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist, Neuropharmacology, 31, 1027, 10.1016/0028-3908(92)90104-W · doi:10.1016/0028-3908(92)90104-w
  113. Fumagalli, 1998, Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter, J. Neurosci., 18, 4861, 10.1523/JNEUROSCI.18-13-04861.1998 · DOI · Paper page
  114. Fumagalli, 1999, Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice, J. Neurosci., 19, 2424, 10.1523/JNEUROSCI.19-07-02424.1999 · DOI · Paper page
  115. Gangarossa, 2012, Characterization of dopamine D1 and D2 receptor-expressing neurons in the mouse hippocampus, Hippocampus, 22, 2199, 10.1002/hipo.22044 · DOI · Paper page
  116. Gao, 2008, Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression, Trends Immunol., 29, 357, 10.1016/j.it.2008.05.002 · DOI · Paper page
  117. Garwood, 2006, Amphetamine exposure is elevated in Parkinson's disease, Neurotoxicology, 27, 1003, 10.1016/j.neuro.2006.03.015 · DOI
  118. Gaugler, 2012, Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity, Acta Neuropathol., 123, 653, 10.1007/s00401-012-0963-y · DOI
  119. Giros, 1989, Alternative splicing directs the expression of twoD2 dopamine receptor isoforms, Nature, 342, 923, 10.1038/342923a0 · DOI · Paper page
  120. Golembiowska, 2003, Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats, Neuropharmacology, 45, 484, 10.1016/S0028-3908(03)00209-0 · doi:10.1016/s0028-3908(03)00209-0
  121. Gonzalez-Aparicio, 2014, Oleoylethanolamide reduces l-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson's disease, Neurobiol. Dis., 62, 416, 10.1016/j.nbd.2013.10.008 · DOI · Paper page
  122. Gordon, 1991, Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat, Pharmacol. Biochem. Behav., 38, 339, 10.1016/0091-3057(91)90288-D · DOI · Paper page
  123. Górska, 2014, The effect of caffeine on MDMA-induced hydroxyl radical production in the mouse striatum, Pharmacol. Rep., 66, 718, 10.1016/j.pharep.2014.03.003 · doi:10.1016/j.pharep.2014.03.003
  124. Górska, 2014, The role of adenosine A1 and A2A receptors in the caffeine effect on MDMA-induced DA and 5-HT release in the mouse striatum, Neurotox. Res.
  125. Gouzoulis-Mayfrank, 2003, Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users, Prog. Neuropsychopharmacol. Biol. Psychiatry, 27, 819, 10.1016/S0278-5846(03)00114-3 · DOI
  126. Granado, 2008, D1 but not D5 dopamine receptors are critical for LTP, spatial learning, and LTP-induced arc and zif268 expression in the hippocampus, Cereb. Cortex, 18, 1, 10.1093/cercor/bhm026 · DOI · Paper page
  127. Granado, 2008, Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice, J. Neurochem., 107, 1102, 10.1111/j.1471-4159.2008.05705.x · DOI
  128. Granado, 2008, Early loss of dopaminergic terminals in striosomes after MDMA administration to mice, Synapse, 62, 80, 10.1002/syn.20466 · DOI
  129. Granado, 2010, Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration: early loss of TH in striosomes after methamphetamine, Neurotox. Res., 18, 48, 10.1007/s12640-009-9106-1 · DOI
  130. Granado, 2011, Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA, Neurobiol. Dis., 42, 391, 10.1016/j.nbd.2011.01.033 · DOI
  131. Granado, 2011, Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum, Glia, 59, 1850, 10.1002/glia.21229 · DOI
  132. Granado, 2013, Methamphetamine and Parkinson's disease, Parkinson's Dis., 10.1155/2013/308052 · DOI
  133. Granado, 2014, D1 but not D4 dopamine receptors are critical for MDMA-induced neurotoxicity in mice, Neurotox. Res., 25, 100, 10.1007/s12640-013-9438-8 · DOI
  134. Grant, 2012, Methamphetamine-associated psychosis, J. Neuroimmune Pharmacol., 7, 113, 10.1007/s11481-011-9288-1 · DOI · Paper page
  135. Green, 1992, The neurotoxic effects of methamphetamine on 5-hydroxytryptamine and dopamine in brain: evidence for the protective effect of chlormethiazole, Neuropharmacology, 31, 315, 10.1016/0028-3908(92)90062-T · DOI
  136. Green, 2002, On the anxiogenic and anxiolytic nature of long-term cerebral 5-HT depletion following MDMA, Psychopharmacology (Berl.), 164, 448, 10.1007/s00213-002-1158-3 · DOI
  137. Green, 2004, A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response, Eur. J. Pharmacol., 500, 3, 10.1016/j.ejphar.2004.07.006 · DOI · Paper page
  138. Green, 2005, Studies on the effect of MDMA (‘ecstasy’) on the body temperature of rats housed at different ambient room temperatures, Br. J. Pharmacol., 146, 306, 10.1038/sj.bjp.0706318 · DOI
  139. Green, 2012, Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans, Br. J. Pharmacol., 166, 1523, 10.1111/j.1476-5381.2011.01819.x · DOI · Paper page
  140. Gross, 2011, Striatal dopamine D1 and D2 receptors: widespread influences on methamphetamine-induced dopamine and serotonin neurotoxicity, Synapse, 65, 1144, 10.1002/syn.20952 · DOI
  141. Gudelsky, 1986, Suppression of the hypo- and hyperthermic responses to 5-HT agonists following the repeated administration of monoamine oxidase inhibitors, Psychopharmacology (Berl.), 90, 403, 10.1007/BF00179199 · DOI
  142. Gudelsky, 1996, Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin, J. Neural Transm., 102, 1397, 10.1007/BF01271253 · DOI
  143. Gudelsky, 2008, Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons, Pharmacol. Biochem. Behav., 90, 198, 10.1016/j.pbb.2007.10.003 · DOI
  144. Guilarte, 2003, Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity, Neuroscience, 122, 499, 10.1016/S0306-4522(03)00476-7 · DOI
  145. Guillot, 2008, Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis, J. Neurochem., 106, 2205, 10.1111/j.1471-4159.2008.05568.x · DOI
  146. Hadlock, 2010, Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation, J. Pharmacol. Exp. Ther., 335, 207, 10.1124/jpet.110.166660 · DOI
  147. Hall, 2006, Acute toxic effects of ‘Ecstasy’ (MDMA) and related compounds: overview of pathophysiology and clinical management, Br. J. Anaesth., 96, 678, 10.1093/bja/ael078 · DOI · Paper page
  148. Hansen, 2002, Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity, J. Pharmacol. Exp. Ther., 300, 1093, 10.1124/jpet.300.3.1093 · DOI
  149. Hardman, 1973, Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals, Toxicol. Appl. Pharmacol., 25, 229, 10.1016/S0041-008X(73)80016-X · DOI
  150. Hatzidimitriou, 1999, Altered serotonin innervations patterns in the forebrain of monkeys treated with (+/−)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery, J. Neurosci., 19, 5096, 10.1523/JNEUROSCI.19-12-05096.1999 · DOI · Paper page
  151. Hedreen, 1995, Early loss of neostriatal striosome neurons in Huntington's disease, J. Neuropathol. Exp. Neurol., 54, 105, 10.1097/00005072-199501000-00013 · DOI · Paper page
  152. Henley, 1989, Localization and quantitative autoradiography of glutamatergic ligand binding sites in chick brain, Eur. J. Neurosci., 1, 516, 10.1111/j.1460-9568.1989.tb00358.x · DOI
  153. Hernandez-Rabaza, 2010, Neurotoxicity and persistent cognitive deficits induced by combined MDMA and alcohol exposure in adolescent rats, Addict. Biol., 15, 413, 10.1111/j.1369-1600.2010.00259.x · DOI
  154. Herndon, 2014, Glial cell response to 3,4-(+/−)-methylenedioxymethamphetamine and its metabolites, Toxicol. Sci., 138, 130, 10.1093/toxsci/kft275 · DOI
  155. Hirata, 1997, P53-knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies, J. Neurochem., 69, 780, 10.1046/j.1471-4159.1997.69020780.x · DOI · Paper page
  156. Huang, 2015, Caspase-11 plays an essential role in methamphetamine-induced dopaminergic neuron apoptosis, Toxicol Sci., 10.1093/toxsci/kfv014 · DOI
  157. Hurley, 2013, Neuroinflammation, neurodegeneration, and depression, Neurotox. Res., 23, 131, 10.1007/s12640-012-9348-1 · DOI · Paper page
  158. Hurtig, 2000, Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease, Neurology, 54, 1916, 10.1212/WNL.54.10.1916 · DOI · Paper page
  159. Imam, 2001, Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase, J. Neurochem., 76, 745, 10.1046/j.1471-4159.2001.00029.x · DOI · Paper page
  160. Insel, 1989, 3,4-Methylenedioxymethamphetamine (“ecstasy”) selectively destroys brain serotonin terminals in rhesus monkeys, J. Pharmacol. Exp. Ther., 249, 713, 10.1016/S0022-3565(25)23487-5 · DOI · Paper page
  161. Iravani, 2005, A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets, Eur. J. Neurosci., 21, 841, 10.1111/j.1460-9568.2005.03915.x · DOI
  162. Itzhak, 2003, Relevance of MDMA (“ecstasy”)-induced neurotoxicity to long-lasting psychomotor stimulation in mice, Psychopharmacology (Berl.), 166, 241, 10.1007/s00213-002-1320-y · DOI
  163. Izco, 2010, Administration of neurotoxic doses of MDMA reduces sensitivity to ethanol and increases GAT-1 immunoreactivity in mice striatum, Psychopharmacology (Berl.), 207, 671, 10.1007/s00213-009-1699-9 · DOI
  164. Jacobs, 1999, Activity of serotonergic neurons in behaving animals, Neuropsychopharmacology, 21, 9S, 10.1016/S0893-133X(99)00012-3 · DOI · Paper page
  165. Jayanthi, 1999, Overexpression of human copper/zinc superoxide dismutase in transgenic mice attenuates oxidative stress caused by methylenedioxymethamphetamine (Ecstasy), Neuroscience, 91, 1379, 10.1016/S0306-4522(98)00698-8 · DOI
  166. Jayanthi, 2005, Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis, Proc. Natl. Acad. Sci. U. S. A., 102, 868, 10.1073/pnas.0404990102 · DOI · Paper page
  167. Jiang, 2014, The effects of a low and escalating dosing regimen of methamphetamine on spontaneous behaviors of rhesus macaques (Macaca mulatta), Drug Alcohol Depend., 140, e86, 10.1016/j.drugalcdep.2014.02.280 · doi:10.1016/j.drugalcdep.2014.02.280
  168. Jiang, 2014, Epigenetic upregulation of alpha-synuclein in the rats exposed to methamphetamine, Eur. J. Pharmacol., 745, 243, 10.1016/j.ejphar.2014.10.043 · doi:10.1016/j.ejphar.2014.10.043
  169. Johnson, 2005, Acute hypercarbic gas exposure reveals functionally distinct subpopulations of serotonergic neurons in rats, J. Psychopharmacol., 19, 327, 10.1177/0269881105053281 · DOI · Paper page
  170. Kelly, 2012, Chronic exposure to corticosterone enhances the neuroinflammatory and neurotoxic responses to methamphetamine, J. Neurochem., 122, 995, 10.1111/j.1471-4159.2012.07864.x · DOI · Paper page
  171. Khairnar, 2010, Caffeine enhances astroglia and microglia reactivity induced by 3,4-methylenedioxymethamphetamine (‘ecstasy’) in mouse brain, Neurotox. Res., 17, 435, 10.1007/s12640-009-9125-y · DOI
  172. Khairnar, 2014, Antagonism of adenosine A1 or A2A receptors amplifies the effects of MDMA on glial activation in the mouse brain: relevance to caffeine–MDMA interactions, J. Caffeine Res., 4, 41, 10.1089/jcr.2014.0006 · DOI
  173. Kindlundh-Högberg, 2007, Repeated intermittent MDMA binges reduce DAT density in mice and SERT density in rats in reward regions of the adolescent brain, Neurotoxicology, 28, 1158, 10.1016/j.neuro.2007.07.002 · DOI
  174. King, 2010, Psychiatric symptoms and HPA axis function in adolescent methamphetamine users, J. Neuroimmune Pharmacol., 5, 582, 10.1007/s11481-010-9206-y · DOI
  175. Kish, 2010, Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study, Brain, 133, 1779, 10.1093/brain/awq103 · DOI · Paper page
  176. Kovács, 2007, Single dose of MDMA causes extensive decrement of serotoninergic fibre density without blockage of the fast axonal transport in Dark Agouti rat brain and spinal cord, Neuropathol. Appl. Neurobiol., 33, 193, 10.1111/j.1365-2990.2006.00790.x · DOI
  177. Krasnova, 2009, Methamphetamine toxicity and messengers of death, Brain Res. Rev., 60, 379, 10.1016/j.brainresrev.2009.03.002 · DOI · Paper page
  178. Krasnova, 2014, Incubation of methamphetamine and palatable food craving after punishment-induced abstinence, Neuropsychopharmacology, 39, 2008, 10.1038/npp.2014.50 · DOI
  179. Kvernmo, 2006, A review of the receptor binding and pharmacokinetic properties of dopamine agonists, Clin. Ther., 28, 1065, 10.1016/j.clinthera.2006.08.004 · DOI · Paper page
  180. Leonardi, 1994, MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac), Neuropsychopharmacology, 10, 231, 10.1038/npp.1994.26 · DOI · Paper page
  181. Li, 2013, Depression and alterations in hypothalamic-pituitary-adrenal and hypothalamic-pituitary-thyroid axis function in male abstinent methamphetamine abusers, Hum. Psychopharmacol., 28, 477, 10.1002/hup.2335 · DOI
  182. Lim, 2014, Striatal cholinergic interneuron regulation and circuit effects, Front. Synaptic Neurosci., 21, 6
  183. Lipton, 1994, Mechanisms of disease: excitatory amino acids as a final common pathway for neurologic disorders, N. Engl. J. Med., 330, 613, 10.1056/NEJM199403033300907 · DOI · Paper page
  184. Liu, 2009, Alpha-synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity, Neurosci. Lett., 454, 187, 10.1016/j.neulet.2009.02.056 · DOI · Paper page
  185. Lopez-Rodriguez, 2014, Sex-dependent long-term effects of adolescent exposure to THC and/or MDMA on neuroinflammation and serotoninergic and cannabinoid systems in rats, Br. J. Pharmacol., 171, 1435, 10.1111/bph.12519 · DOI · Paper page
  186. Lyles, 2003, Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms, Brain Res. Rev., 42, 155, 10.1016/S0165-0173(03)00173-5 · DOI · Paper page
  187. Malberg, 1996, Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat, J. Pharmacol. Exp. Ther., 278, 258, 10.1016/S0022-3565(25)20131-8 · DOI
  188. Manning-Boğ, 2007, Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter, Neurobiol. Dis., 27, 141, 10.1016/j.nbd.2007.03.014 · DOI
  189. Martín, 2008, Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors, Neuropsychopharmacology, 33, 1667, 10.1038/sj.npp.1301558 · DOI
  190. Mata, 2015, Methamphetamine decreases CD4 T cell frequency and alters pro-inflammatory cytokine production in a model of drug abuse, Eur. J. Pharmacol., 752C, 26, 10.1016/j.ejphar.2015.02.002 · DOI
  191. McCann, 1999, Cognitive performance in (+/−)3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) users: a controlled study, Psychopharmacology (Berl.), 143, 417, 10.1007/s002130050967 · DOI · Paper page
  192. McCann, 2001, Caveat emptor: editors beware, Neuropsychopharmacology, 24, 333, 10.1016/S0893-133X(00)00171-8 · DOI
  193. McCann, 2008, Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/−)3,4-methylenedioxymethamphetamine (“ecstasy”) users: relationship to cognitive performance, Psychopharmacology (Berl.), 200, 439, 10.1007/s00213-008-1218-4 · DOI · Paper page
  194. McGuinness, 2006, Methamphetamine abuse, Am. J. Nurs., 106, 54, 10.1097/00000446-200612000-00024 · DOI
  195. McNamara, 2006, Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines. MDMA (“Ecstasy”) and MDA (“Love”), Neuropharmacology, 50, 69, 10.1016/j.neuropharm.2005.08.006 · DOI
  196. Mechan, 2002, The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA “ecstasy”) to rats, Br. J. Pharmacol., 135, 170, 10.1038/sj.bjp.0704442 · DOI · Paper page
  197. Medina, 1996, Differential abundance of glutamate transporter subtypes in amyotrophic lateral sclerosis (ALS)-vulnerable versus ALS resistant brain stem motor cell groups, Exp. Neurol., 142, 287, 10.1006/exnr.1996.0198 · DOI
  198. Melega, 1997, Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey, Brain Res., 766, 113, 10.1016/S0006-8993(97)00548-9 · DOI
  199. Melega, 2008, Long-term methamphetamine administration in the vervet monkey models aspects of a human exposure: brain neurotoxicity and behavioral profiles, Neuropsychopharmacology, 33, 1441, 10.1038/sj.npp.1301502 · DOI
  200. Meredith, 2005, Implications of chronic methamphetamine use: a literature review, Harv. Rev. Psychiatry, 13, 141, 10.1080/10673220591003605 · DOI · Paper page

200 of 319 shown

Cited by

See all 225

Metadata

Authors
Moratalla, R., Khairnar, A., Simola, N., Granado, N., García-Montes, J. R., Porceddu, P. F., Tizabi, Y., Costa, G., & Morelli, M.
Venue
Progress in Neurobiology
Publisher
Elsevier BV
Published
2017-08
Volume
155
Pages
149-170
ISSN
0301-0082 (ISSN-L)
OpenAlex
W2194633751
Cited by
225
References
24
FWCI
7.28
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms. https://app.cochat.ai/papers/10.1016/j.pneurobio.2015.09.011
The paper
Moratalla, R., Khairnar, A., Simola, N., Granado, N., García-Montes, J. R., Porceddu, P. F., Tizabi, Y., Costa, G., & Morelli, M. (2017). Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms. Progress in Neurobiology. https://doi.org/10.1016/j.pneurobio.2015.09.011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.